Alvotech

ALVO · Nasdaq · Luxembourg

Share price · ALVO

$4.55+0.60 (+15.19%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.6M (1.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ALVO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Nov 2026-10.3%
  2. 5 Oct 2026+12.1%
  3. 18 Sep 2026+9.9%
  4. 24 Aug 2026+18.5%
  5. 31 Jul 2026+15.4%
  6. 29 Jul 2026+13.9%
  7. 22 Jun 2026-6.9%
  8. 8 Jun 2026+19.8%
  9. 4 Jun 2026+19.1%
  10. 11 May 2026+10.1%

Share of unusual movement by asset

For each asset, the share of ALVO's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—55%
Sessions with no dated event—45%

No dated announcements about its assets since 3 Sep 2025.

Assets

(4 total)
4Total Assets
2Approved
0Phase 3 / Filed
2Phase 1–2 / Early
7Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis
Ulcerative Colitis, Crohn's Disease
Approved
IL-12 p40Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease
Preclinical / Unstaged
VEGF-AProtein / enzyme therapeutic
Age-Related Macular Degeneration
Preclinical / Unstaged
VEGF-AProtein / enzyme therapeutic
Age-Related Macular Degeneration

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (2)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$306M$93M$151M—report ↗
View 1 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-H1$236M$97M$11M$77Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$586M$184M$172M—-$50M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$490M$171M$51M$58M-$237M operating cash flowreport ↗
2023-FY$91M$211M$11M$138M-$312M operating cash flowreport ↗
2022-FY$83M$181M$66M$128M-$312M operating cash flowreport ↗
2021-FY$37M$191M$18M$25M-$228M operating cash flowreport ↗

Insider transactions

This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.